Disturbances of Modulating Molecules (FOXP3, CTLA-4/CD28/B7, and CD40/CD40L) MRNA Expressions in the Orbital Tissue from Patients with Severe Graves' Ophthalmopathy

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2015 Feb 6

PMID 25653477

Citations 10

Authors

Przemyslaw Pawlowski

Natalia Wawrusiewicz-Kurylonek

Anja Eckstein

Joanna Reszec

Wlodzimierz Luczynski

Kristian Johnson

Adam Kretowski

Alina Bakunowicz-Lazarczyk

Maria Gorska

Jacek Szamatowicz

Lech Chyczewski

Janusz Mysliwiec

Affiliations

Soon will be listed here.

Abstract

Purpose. To evaluate the relationship between the expression of orbital tissue mRNA for FOXP3, CTLA-4/CD28/CD80/CD86, and CD40/CD40 and the severity of Graves' orbitopathy (GO). Material and Methods. Orbital tissue was obtained from 26 patients with GO, with mild (n = 6) or severe GO (n = 20), and 7 healthy controls. The expression of mRNA of FOXP3, CTLA-4/CD28/CD80/CD86, CD40/CD40L was measured by RT-PCR. TCR and CD3 were evaluated by immunohistochemistry. Results. Higher mRNA for FoxP3 (relative expression: 1.4) and CD40 (1.27) and lower expression of CTLA-4 (0.61) were found in the GO tissues versus controls. In severe GO as compared to mild GO higher mRNA expression for FoxP3 (1.35) and CD40 (1.4) and lower expression for CTLA-4 (0.78), CD28 (0.62), and CD40L (0.56) were found. A positive correlation was found between FOXP3 mRNA and CD3 infiltration (R = 0.796, P = 0.0000001). Conclusions. The enhanced FOXP3 mRNA expression in GO samples may suggest the dysfunction of FOXP3 cells in the severe GO. The diminished mRNA expression of CTLA-4 in severe GO may indicate inadequate T regulatory function. The enhanced mRNA expression of CD40 in severe GO and negative correlation to CRP mRNA may suggest their role in the active and inactive GO.

Citing Articles

Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review.

Wu K, Yakobi Y, Gueorguieva D, Mazerolle E Biomedicines. 2024; 12(11).

PMID: 39595113 PMC: 11592388. DOI: 10.3390/biomedicines12112547.

A Comprehensive Review of Thyroid Eye Disease Pathogenesis: From Immune Dysregulations to Novel Diagnostic and Therapeutic Approaches.

Kulbay M, Tanya S, Tuli N, Dahoud J, Dahoud A, Alsaleh F Int J Mol Sci. 2024; 25(21).

PMID: 39519180 PMC: 11546489. DOI: 10.3390/ijms252111628.

Immune checkpoints: new insights into the pathogenesis of thyroid eye disease.

Shu X, Shao Y, Chen Y, Zeng C, Huang X, Wei R Front Immunol. 2024; 15:1392956.

PMID: 38817600 PMC: 11137266. DOI: 10.3389/fimmu.2024.1392956.

Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets.

Cieplinska K, Niedziela E, Kowalska A J Clin Med. 2024; 13(1).

PMID: 38202079 PMC: 10780108. DOI: 10.3390/jcm13010072.

Role of Peripheral Regulatory T Lymphocytes in Patients with Thyroid Associated Ophthalmopathy During Systemic Glucocorticoid Treatment: A Prospective Observational Study.

Xu Q, Zhang X, Luo B, Li T, Yuan G, Shao S Curr Med Sci. 2022; 43(1):130-138.

PMID: 36459302 DOI: 10.1007/s11596-022-2671-8.

References

Eckstein A, Lax H, Losch C, Glowacka D, Plicht M, Mann K . Patients with severe Graves' ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission. Clin Endocrinol (Oxf). 2007; 67(4):607-12. DOI: 10.1111/j.1365-2265.2007.02933.x. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Kim N, Hatton M . The role of genetics in Graves' disease and thyroid orbitopathy. Semin Ophthalmol. 2008; 23(1):67-72. DOI: 10.1080/08820530701745256. View

Mysliwiec J, Waligorski D, Nikolajuk A, Gorska M . Soluble CD40 and its ligand CD154 in patients with Graves' ophthalmopathy during combined therapy with corticosteroids and teleradiotherapy. Adv Med Sci. 2008; 52:104-8. View

Gianoukakis A, Smith T . Recent insights into the pathogenesis and management of thyroid-associated ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2008; 15(5):446-52. PMC: 3712753. DOI: 10.1097/MED.0b013e32830eb8ab. View

Smith T, Tsai C, Shih M, Tsui S, Chen B, Han R . Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid. 2008; 18(9):983-8. PMC: 2574420. DOI: 10.1089/thy.2007.0404. View

Villanueva R, Inzerillo A, Tomer Y, Barbesino G, Meltzer M, Concepcion E . Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid. 2000; 10(9):791-8. DOI: 10.1089/thy.2000.10.791. View

Ye F, Hou P, Wu X, Ma X, Gao L, Wu L . The significance of immune-related molecule expression profiles in an animal model of Graves' disease. Autoimmunity. 2011; 45(2):143-52. DOI: 10.3109/08916934.2011.611548. View

Tomer Y, Concepcion E, Greenberg D . A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease. Thyroid. 2003; 12(12):1129-35. DOI: 10.1089/105072502321085234. View

10.

Vaidya B, Oakes E, Imrie H, Dickinson A, Perros P, Kendall-Taylor P . CTLA4 gene and Graves' disease: association of Graves' disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clin Endocrinol (Oxf). 2003; 58(6):732-5. DOI: 10.1046/j.1365-2265.2003.01778.x. View

11.

Ban Y, Davies T, Greenberg D, Kissin A, Marder B, Murphy B . Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease. Genes Immun. 2003; 4(8):586-93. DOI: 10.1038/sj.gene.6364018. View

12.

Ban Y, Tomer Y . The contribution of immune regulatory and thyroid specific genes to the etiology of Graves' and Hashimoto's diseases. Autoimmunity. 2003; 36(6-7):367-79. DOI: 10.1080/08916930310001603037. View

13.

Prabhakar B, Bahn R, Smith T . Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev. 2003; 24(6):802-35. DOI: 10.1210/er.2002-0020. View

14.

Freeman G, Boussiotis V, Anumanthan A, Bernstein G, Ke X, Rennert P . B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4. Immunity. 1995; 2(5):523-32. DOI: 10.1016/1074-7613(95)90032-2. View

15.

Sempowski G, ROZENBLIT J, Smith T, Phipps R . Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol. 1998; 274(3):C707-14. DOI: 10.1152/ajpcell.1998.274.3.C707. View

16.

Sigal L, Reiser H, Rock K . The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo. J Immunol. 1998; 161(6):2740-5. View

17.

Vaidya B, Imrie H, Perros P, Dickinson J, McCarthy M, Kendall-Taylor P . Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet. 1999; 354(9180):743-4. DOI: 10.1016/S0140-6736(99)01465-8. View

18.

Smith T, Sciaky D, Phipps R, Jennings T . CD40 expression in human thyroid tissue: evidence for involvement of multiple cell types in autoimmune and neoplastic diseases. Thyroid. 1999; 9(8):749-55. DOI: 10.1089/thy.1999.9.749. View

19.

Jacobson E, Concepcion E, Oashi T, Tomer Y . A Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology. 2005; 146(6):2684-91. DOI: 10.1210/en.2004-1617. View

20.

Feldon S, Park D, OLoughlin C, Nguyen V, Landskroner-Eiger S, Chang D . Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy. Invest Ophthalmol Vis Sci. 2005; 46(11):3913-21. DOI: 10.1167/iovs.05-0605. View